In its main clinical trial, mRNA-1010 was shown to be 26.6% more effective than the comparator flu shot in adults aged 50 ...
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient ...
In a news release late Tuesday, Moderna said it was blindsided by the FDA’s refusal, which the FDA cited as being due to the design of the company’s Phase 3 trial for its mRNA flu vaccine, dubbed mRNA ...
Moderna (MRNA) stock fell 9% premarket after FDA rejected its flu vaccine application due to trial design issues, despite ...
Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has ...
Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...
3don MSNOpinion
“The real agenda is rejecting science”: FDA unexpectedly nixes new Moderna flu vaccine
The move is further in line with HHS Secretary Kennedy's anti-vaccine policies ...
Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010.
CONCERNS that Highlands College has an “outdated” campus and that the Island’s vocational training infrastructure is “highly fragmented” – with limited opportunities for adults to upskill or retrain – ...
"The FDA rejected Moderna's application for filing because the company refused to follow very clear FDA guidance from 2024 to ...
The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results